17:32 , Nov 11, 2016 |  BioCentury  |  Emerging Company Profile

Golden opportunity

By applying medicinal chemistry to an old drug with strong but narrow-spectrum antibacterial properties, Auspherix Ltd. has discovered a new class of gold salt derivatives called organogolds that could preferentially target desired tissues to fight...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Domainex, Auspherix deal

Auspherix Ltd. (Stevenage, U.K.) (formerly Auspherix Pty. Ltd.) and Domainex extended a research contract through 2017 a 2014 deal to develop drugs to treat antibiotic-resistant bacterial infections. Under the extension, the partners will refine a...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Financial News

Auspherix completes venture financing

Auspherix Ltd. , Stevenage, U.K.   Business: Infectious   Date completed: 2015-06-03   Type: Venture financing   Raised: L6 million ($9.2 million)   Investors: Imperial Innovations Group plc ; Medical Research Commercialization Fund   Note:...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Financial News

Auspherix completes venture financing

Auspherix Pty. Ltd. , Sydney, Australia   Business: Infectious   Date completed: 2014-10-23   Type: Venture financing   Raised: A$1 million ($876,000)   Investor: Medical Research Commercialization Fund  ...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

Auspherix infectious news

Auspherix debuted with A$1 million ($914,700) in seed funding from Australia's Medical Research Commercialization Fund (MRCF) to develop antibiotics to treat resistant bacterial diseases. The newco will in-license IP from the ithree institute at the...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Financial News

Auspherix completes venture financing

Auspherix Pty. Ltd. , Sydney, Australia   Business: Infectious   Date completed: 12/3/13   Type: Venture financing   Raised: A$1 million ($914,700)   Investor: Medical Research Commercialization Fund  ...
01:17 , Dec 4, 2013 |  BC Extra  |  Financial News

Auspherix debuts with funding from MRCF

Auspherix Pty. Ltd. (Sydney, Australia) debuted on Tuesday with A$1 million ($914,700) in seed funding from Australia's Medical Research Commercialization Fund (MRCF) to develop antibiotics to treat resistant bacterial diseases. The newco will in-license IP...